Recently, the China National Medical Products Administration（NMPA) granted approval to a groundbreaking 9-valent HPV vaccine, Cecolin^®9, jointly developed by Xiamen Innovax Biotech Co., Ltd and Xiamen University. This milestone makes China the second country in the world, after the United States, capable of independently manufacturing and supplying the 9-valent HPV vaccine.

Cecolin^®9 has been approved for females aged 9 to 45, offering broad protection against cervical cancer. For girls aged 9 to 17, a two-dose schedule is available, which makes immunization more convenient. Notably, it is currently the only HPV vaccine in China approved for a two-dose regimen in girls aged 15 to 17.

Renowned for its high production capacity, outstanding quality and proven safety, Cecolin^®9 sets a new standard for HPV vaccination. This breakthrough will expand access to high-quality HPV vaccines nationwide, safeguarding millions of women and girls with stronger health protection against cervical cancer.